Schoenhaus v. Genesco, Inc.

440 F.3d 1354, 78 U.S.P.Q. 2d (BNA) 1252, 2006 U.S. App. LEXIS 6172, 2006 WL 626073
CourtCourt of Appeals for the Federal Circuit
DecidedMarch 15, 2006
Docket2005-1278
StatusPublished
Cited by14 cases

This text of 440 F.3d 1354 (Schoenhaus v. Genesco, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schoenhaus v. Genesco, Inc., 440 F.3d 1354, 78 U.S.P.Q. 2d (BNA) 1252, 2006 U.S. App. LEXIS 6172, 2006 WL 626073 (Fed. Cir. 2006).

Opinion

MICHEL, Chief Judge.

Plaintiffs Harold D. Schoenhaus and Richard M. Jay appeal the decision of the United States District Court for the Eastern District of Pennsylvania granting summary judgment of non-infringement of their United States Patent No. 5,174,052 (“the ’052 patent”) to defendants Genesco, Inc. and Johnston & Murphy, Inc. Schoenhaus v. Genesco, Inc., 351 F.Supp.2d 320 (E.D.Pa.2005). The district court correctly held that the limitations of claim 1 must be found in a removable orthotic insert, or the immovable insert portion of a shoe, and may not be provided by other parts of the construction of the shoe. Likewise, the district court correctly held that the “heel seat” of the removable insert or immovable insert portion must itself be “rigid”, not rigid only in conjunction with the rear of the upper of the shoe, and not merely semi-rigid. Because the district court correctly concluded as a matter of law that the rigidity limitation of claim 1 is missing from the insert portion of the accused shoe, we affirm.

I

Co-inventors Drs. Schoenhaus and Jay are co-owners of the ’052 patent, entitled “Dynamic Stabilizing Inner Sole System”. According to the abstract, the invention is directed to “[a]n orthotic device for preventing hyperpronation of a human foot”, which is a condition involving excessive flattening of the arch of the foot, in which the foot rotates inwardly while a person is walking, causing problems such as heel spurs, bunions and hammertoes. The invention works by maintaining the heel bone in proper alignment relative to the. leg, approximately five degrees of varus, and differs from the prior art in that it controls relative heel position entirely through the interior of the “heel seat”, which cups the heel. In contrast, other orthotics provide heel inversion through portions of the shoe construction by incorporating, for example, an “extrinsic wedge” built into the shoe’s insole that tilts the foot.

When the application that matured into the ’052 patent was pending, plaintiffs contacted the defendants in an attempt to arrange a license. After the defendants signed a confidential disclosure agreement, the defendants made a prototype shoe using the invention and the parties exchanged draft license agreements. However, after two-and-a-half years, the defendants withdrew from negotiations. Eight years later, in 2002, Dr. Schoenhaus entered a Johnston & Murphy store and came upon what he believed to be an infringing line of footwear. The plaintiffs promptly filed suit against the defendants *1356 alleging infringement of the ’052 patent, misappropriation of trade secrets, conversion, and unjust enrichment. In response, defendants asserted a counterclaim of invalidity.

On January 10, 2005, the district court granted defendants’ motion for summary judgment of non-infringement. Senior Judge Louis H. Poliak did not issue a separate Markman order; rather, in a carefully-crafted summary judgment opinion, he construed two limitations of claim 1 of the patent and found as a matter of law that neither limitation was present in the accused shoes. Id. at 324-26. Accordingly, Judge Poliak entered final judgment under Federal Rule of Civil Procedure 54(b) in favor of defendants of non-infringement, dismissed defendants’ counterclaim of invalidity as moot, and stayed further proceedings on the state law claims pending our review of the infringement question. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

II

The primary issue on appeal is whether the limitations of claim 1 of the ’052 patent must be found in a removable orthotic insert or the immovable insert portion of a shoe, or whether some of the limiting features may be provided, at least in part, by other parts of the construction of the shoe. Central to this dispute is the meaning of the phrase “orthotic device”. 1 Claims 1 and 2 of the ’052 patent read in relevant part:

1. An orthotic device for preventing hyperpronation of a human foot comprising a deep rigid heel seat to cup the calcaneus, said heel cup being medially offset and laterally tilted by a sufficient amount to maintain the calcaneus in approximately 5 degrees of varus ....
2. A footwear product having as an element thereof an orthotic device as claimed in claim 1.

’052 patent, col. 6,11. 29^42 (emphasis added).

On appeal, plaintiffs argue that the district court erred in its claim construction. This court reviews the meaning and scope of patent claim terms for correctness as a matter of law, that is, without deference, or de novo. Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1454 (Fed.Cir.1998).

A

Plaintiffs contend that the phrase “orthotic device”, and thus the scope of claim 1, is not limited to a “discrete insert (whether it be removable or immovable from a shoe).” Rather, they assert that an “orthotic device” means any “immovable or removable part or parts of an actual shoe that is designed to activate or supplement a weakened or atrophied limb or function.” In short, plaintiffs urge this court to adopt a claim construction that allows other parts of the shoe — not just the insert or immovable insert portion — to meet claim limitations.

In support of this argument, plaintiffs point to language in the specification that states that their “invention” is both an insert and a “shoe [] built to have the shape of the interior of the insert”. ’052 patent, col. 4,11. 44-45. Plaintiffs’ contention regarding the invention as disclosed is correct; however, the term “orthotic device”, as used in the claims, has a specific meaning which must be determined from the intrinsic evidence. See Phillips v. AWH Corp., 415 F.3d 1303, 1317 (Fed.Cir.2005) (en banc). In other words, the question before this court is not what the *1357 invention covers, but whether the claim term “orthotic device”, as used in the patent, and thus the subsidiary limitations of claim 1, such as “rigid heel seat”, refer only to a removable orthotic insert or the immovable insert portion of a shoe, or more generally to a shoe built to have the shape of the interior of the insert.

We begin our analysis with the usage of the term “orthotic device” in the patent claims. The term appears in claims 1 and 2 of the patent, and there is a “presumption that the same terms appearing in different portions of the claims should be given the same meaning unless it is clear from the specification and prosecution history that the terms have different meanings at different portions of the claims.” Fin Control Sys. Pty., Ltd. v. OAM, Inc., 265 F.3d 1311, 1318 (Fed.Cir.2001).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wanker v. United States
Federal Claims, 2021
Media Digital v. Toshiba America
2015 DNH 088 (D. New Hampshire, 2015)
SkinMedica, Inc. v. Histogen Inc.
869 F. Supp. 2d 1176 (S.D. California, 2012)
LG Electronics U.S.A., Inc. v. Whirlpool Corp.
798 F. Supp. 2d 541 (D. Delaware, 2011)
Tecsec, Inc. v. International Business MacHines Corp.
769 F. Supp. 2d 997 (E.D. Virginia, 2011)
Becton, Dickinson & Co. v. Tyco Healthcare Group, LP
616 F.3d 1249 (Federal Circuit, 2010)
TIP Systems, LLC v. Phillips & Brooks/Gladwin, Inc.
529 F.3d 1364 (Federal Circuit, 2008)
RFID TRACKER LTD. v. Wal-Mart Stores, Inc.
545 F. Supp. 2d 571 (E.D. Texas, 2008)
Engineered Data Products, Inc. v. GBS CORP.
506 F. Supp. 2d 461 (D. Colorado, 2007)
Affymetrix, Inc. v. Illumina, Inc.
446 F. Supp. 2d 277 (D. Delaware, 2006)
Biovail Laboratories International SRL v. Impax Laboratories, Inc.
433 F. Supp. 2d 501 (E.D. Pennsylvania, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
440 F.3d 1354, 78 U.S.P.Q. 2d (BNA) 1252, 2006 U.S. App. LEXIS 6172, 2006 WL 626073, Counsel Stack Legal Research, https://law.counselstack.com/opinion/schoenhaus-v-genesco-inc-cafc-2006.